Japan Pushing For Vaccine Advisory Committee To Address Drug Lag - PhRMA Symposium
This article was originally published in PharmAsia News
Executive Summary
TOKYO - The drug lag in Japan includes a substantial vaccine lag, which is amplified by the lack of a command center to draw up Japan's vaccination policies, plans and programs like U.S. FDA's Advisory Committee on Immunization Practices and the UK's Joint Committee on Vaccination and Immunization. Now, an official from the Ministry of Health Labor and Welfare's Office of Vaccination Policy Reform suggests the agency adopt a similar committee
You may also be interested in...
Pfizer's Prevnar, Sanofi-Aventis' ActHIB Vaccines Temporarily Suspended In Japan; Safety Committee Unwilling To Lift Action After First Meeting
TOKYO - Japan's Ministry of Health, Labor and Welfare temporarily suspended Pfizer Inc.'s Prevnar and Sanofi-Aventis SA's ActHIB following the death of four infants and now the companies find themselves in front of Japan's cautious safety council awaiting a decision that has the potential to have a large commercial impact, particularly on the blockbuster Prevnar, the latest iteration of which - Prevnar 13, a 13-valent vaccine for both children and adults - is currently in Phase III trials in Japan
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).